Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Rapamycin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    60 result(s) found for: Rapamycin. Displaying page 2 of 3.
    « Previous 1  2  3  Next»
    EudraCT Number: 2004-000973-69 Sponsor Protocol Number: 0468H1-318-WW Start Date*: 2005-04-21
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc
    Full Title: A Randomized, Open-Label, Comparative Evaluation of the Safety and Efficacy of Sirolimus versus Cyclosporine when Combined in a Regimen Containing Basiliximab, Mycophenolate Mofetil, and Corticoste...
    Medical condition: The rationale for the present study is to assess whether a CNI-free regimen including antibody induction, sirolimus, and mycophenolate mofetil (MMF) results in improved long-term renal function wit...
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SE (Prematurely Ended) AT (Completed) GB (Completed) CZ (Prematurely Ended) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2023-000127-36 Sponsor Protocol Number: KIH22001 Start Date*: 2023-04-04
    Sponsor Name:Karolinska Institutet
    Full Title: Evaluating rapamycin treatment in Alzheimer’s disease using positron emission tomography (ERAP)
    Medical condition: Alzheimer's disease (AD) and mild cognitive impairment (MCI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001897 Alzheimer's disease (incl subtypes) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000935-27 Sponsor Protocol Number: 0468H1-313-EU Start Date*: 2005-06-15
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc.Clinical Research & Development Department
    Full Title: A Randomized, Open-label, Comparative Evaluation of Conversion from Calcineurin Inhibitor Treatment to Sirolimus Treatment Versus Continued Calcineurin Inhibitor Treatment in Liver Allograft Recipi...
    Medical condition: Liver allograft recipients under maintenance therapy
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2018-001469-18 Sponsor Protocol Number: CT2-04-17 Start Date*: 2019-04-17
    Sponsor Name:Dipartimento di Scienze della Vita e Biotecnologie dell'Università degli Studi di Ferrara
    Full Title: Treatment of beta-thalassemia patients with rapamycin (sirolimus): from pre-clinical research to a clinical trial
    Medical condition: Beta-thalassemia transfusion dependent patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10043391 Thalassaemia beta PT
    20.0 10010331 - Congenital, familial and genetic disorders 10043391 Thalassaemia beta PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002754-22 Sponsor Protocol Number: BUM-4/GVH Start Date*: 2006-03-14
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: An open, randomized, multicentre phase II pilot study to evaluate the efficacy of budesonide 3 mg effervescent tablet in patients with resistant oral chronic GvHD using different application durati...
    Medical condition: oral chronic graft versus host disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005933-34 Sponsor Protocol Number: SFHI01 Start Date*: 2021-08-09
    Sponsor Name:Sorin CRM SAS (Microport CRM)
    Full Title: Evaluation of a modified Anti-Platelet Therapy associated with low-dose rapamycin DES Firehawk in Acute Myocardial Infarction Patients treated with complete revascularization strategy
    Medical condition: Patients with clinically stable, low to moderate complexity acute Myocardial Infarction (MI; troponine-positive Non-ST-Elevation MI or ST-Elevation MI) requiring primary Percutaneous Coronary Inte...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007541 Cardiac disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing) NL (Trial now transitioned) ES (Ongoing) IT (Ongoing) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005687-44 Sponsor Protocol Number: 0468H1-316 Start Date*: 2015-04-10
    Sponsor Name:Wyeth Research
    Full Title: A Randomized, Open-Label, Comparative Evaluation of Conversion From Calcineurin Inhibitors to Sirolimus Versus Continued Use of Calcineurin Inhibitors in Renal Allograft Recipients
    Medical condition: Renal Transplantation
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-005362-36 Sponsor Protocol Number: SiLVER 05 Start Date*: 2006-06-27
    Sponsor Name:Regensburg University Hospital
    Full Title: A PROSPECTIVE RANDOMISED, OPEN-LABELED, TRIAL COMPARING SIROLIMUS-CONTAINING VERSUS mTOR-INHIBITOR-FREE IMMUNOSUPRESSION IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA
    Medical condition: Prophylaxis against liver transplant rejection in patients undergoing liver transplantation for hepatocellular carcinoma (HCC)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10050434 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) SE (Completed) BE (Completed) NO (Completed) AT (Completed) ES (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001703-32 Sponsor Protocol Number: VASE Start Date*: 2015-11-09
    Sponsor Name:Cliniques Universitaires Saint-Luc (CUSL)
    Full Title: Phase III multicentric study evaluating the efficacy and safety of sirolimus in Vascular Anomalies that are refractory to standard care
    Medical condition: Complex vascular anomalies causing debilitating functional and esthetic impairment that are resistant to standard care
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10047047 Vascular anomalies congenital NEC HLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) DE (Ongoing) NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004042-96 Sponsor Protocol Number: 32-009 Start Date*: 2015-05-05
    Sponsor Name:Santen Incorporated
    Full Title: A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects with Non-Infectious Uveitis of the Posterior...
    Medical condition: non -infectious Uveitis of the Posterior Segment of the Eye
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10036370 Posterior uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-000936-26 Sponsor Protocol Number: 0468E-101467 Start Date*: 2006-01-17
    Sponsor Name:Wyeth Farma, S.A.
    Full Title: Sirolimus en el tratamiento de la nefropatía crónica del injerto demostrada histológicamente
    Medical condition:
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002231-92 Sponsor Protocol Number: AP23573-04-202 Start Date*: Information not available in EudraCT
    Sponsor Name:ARIAD Pharmaceuticals, Inc.
    Full Title: A Phase II Study of AP23573, an mTOR Inhibitor, in Patients with Advanced Sarcoma
    Medical condition: Metastatic and/or unresectable soft tissue or bone sarcoma (excluding GIST).
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005116-12 Sponsor Protocol Number: CRAD001C2428 Start Date*: 2008-03-20
    Sponsor Name:Technical University of Munich
    Full Title: Phase II study of the mTOR-Inhibitor EVEROLIMUS as maintenance therapy in patients aged over 60 years with Mantle Cell Lymphoma (MCL) after first, second, third or fourth line chemotherapy New ...
    Medical condition: Strategies to prolong remission duration in elderly patients with MCL are urgently needed. The effects of Rapamycin derivates on MCL cells in vitro and the evolving in vivo data support the furthe...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003275-40 Sponsor Protocol Number: 63/2007/O/Sper Start Date*: 2008-07-29
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: New immunosuppressive treatments to reduce the rate of recurrence of hepatocellular carcinoma after liver transplantation
    Medical condition: Liver transplantation in patients with hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019695 Hepatic neoplasm LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002310-22 Sponsor Protocol Number: 35/2008/O/Sper Start Date*: 2008-06-16
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: A multicenter phase II trial of Recipient pre-treatment with Short-Term Rapamycin for the prevention of acute GVHD after hematopoietic stem cell transplantation in Elderly Patients
    Medical condition: Graft Versus Host Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10048396 Bone marrow transplant rejection LLT
    9.1 10000802 Acute GVH disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000952-17 Sponsor Protocol Number: NT13403 Start Date*: 2013-04-29
    Sponsor Name:Prague Psychiatric Centre
    Full Title: The Role of mTOR (Mammalian Target of Rapamycin) Signaling Pathway in the Antidepressive Effect of Ketamine in Patients with Depressive Disorder.
    Medical condition: 1. Men and women at the age between 18 to 65 years, with dextromanual dominance. 2. Patients have to answer DSM IV criteria for the major depressive episode, without psychotic symptoms, on the clin...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10012378 Depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004562-10 Sponsor Protocol Number: BUM-5/GVH Start Date*: 2009-07-29
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, randomised, placebo-controlled multicentre phase III clinical study followed by open-label phase on the efficacy and tolerability of budesonide 3 mg effervescent tablet in patients wi...
    Medical condition: Oral chronic graft versus host disease as a complication of haematopoietic stem cell transplantation.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021428 - Immune system disorders 10066261 Chronic graft versus host disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Completed) FR (Completed) SE (Completed) IT (Completed) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001794-28 Sponsor Protocol Number: 806 Start Date*: 2007-10-15
    Sponsor Name:OrbusNeich Medical BV
    Full Title: Endothelial Function following stenting with Genous vs Drug-Eluting Stents
    Medical condition: Patients with symptomatic ischemic heart disease expressing one or two de novo native coronary artery lesions
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011078 Coronary artery disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003056-21 Sponsor Protocol Number: WIRE Start Date*: 2020-02-07
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
    Full Title: Window-of-opportunity clinical trials platform for evaluation of novel treatment strategies in renal cell cancer.
    Medical condition: Surgically resectable renal cell cancer (Stage M0/M1)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038389 Renal cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038389 Renal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-004773-99 Sponsor Protocol Number: RMRCTV1 Start Date*: 2007-09-26
    Sponsor Name:University Hospitals Leicester
    Full Title: A RANDOMISED CONTROLLED TRIAL COMPARING THE USE OF SIROLIMUS BASED BIPHASIC IMMUNOSUPRESSION WITH MYFORTIC TO ALLOW EARLY CNI WITHDRAWAL IN RENAL TRNASPLANTATION
    Medical condition: Chronic Allograft Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    8.1 10063209 Chronic allograft nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 20:49:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA